~~<i id='E808B446A6'><strike id='E808B446A6'><tt id='E808B446A6'><pre id='E808B446A6'></pre></tt></strike></i>~~

Home» explore» fashion

fashion

author：hotspot 2025-09-06 04:57:22 Page View：1

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In boost for rare disease push, AstraZeneca to buy Amolyt Pharma
Next article： Moonlake's readout produced a cash windfall. Risks remain

knowledge

Sports medicine is finally prioritizing gender equality

MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Whathappenswhenanapproveddrugdoesn’twork?Whydon’tpatientswantgenetherapy?AndisMASHstillabigdeal?Weco

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

UK homeowners get some respite as inflation falls by more than anticipated to a 15

SadieJames,right,andJonTaylor,adebtmanageratthecharityChristiansAgainstPoverty,readthedocumentsfroma